Preliminary study of the effects of furosemide on blood pressure during late‐onset pre‐eclampsia in patients with high cardiac output

Tamás, Péter; Hantosi, Eszter; Farkas, Bálint; Ifi, Zsolt; Betlehem, József; Bódis, József

doi:10.1002/ijgo.12019

Cited by 19 publications

(20 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furosemide and droperidol induced gene expression that was contrary to PE. Furosemide is a diuretic that is used to treat eclampsia complicated with intracranial hypertension (46). Droperidol has strong antipsychotic effects that are mainly related to its antagonism to dopamine receptors; it promotes the transformation of dopamine in the brain (47).…”

Section: Discussionmentioning

confidence: 99%

Identifying key genes and drug screening for preeclampsia based on gene expression profiles

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Preeclampsia (PE) is characterized by gestational hypertension and proteinuria, and is a leading cause of maternal death and perinatal morbidity globally. Although the exact cause of PE remains unclear, several studies have suggested a role for abnormal expression of multiple genes. The aim of the present study was to identify key genes and related pathways, and to screen for drugs that regulate these genes for potential PE therapy. The GSE60438 dataset was acquired from the Gene Expression Omnibus database to analyze differentially expressed genes (DEGs). By constructing a protein-protein interaction network and performing reverse transcription-quantitative PCR verification, proteasome 26S subunit, non-ATPase 14, prostaglandin E synthase 3 and ubiquinol-cytochrome c reductase core protein 2 were identified as key genes in PE. In addition, PE was found to be associated with 'circadian rhythm', 'fatty acid metabolism', 'DNA damage response detection of DNA damage', 'regulation of DNA repair' and 'endothelial cell development'. Through connectivity map analysis of DEGs, furosemide and droperidol were suggested to be therapeutic drugs that may target the hub genes for PE treatment. Results analysis of GSEA were included in the discussion section of this article. In conclusion, the current study identified novel key genes associated with the onset of PE and potential drugs for PE treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Identifying key genes and drug screening for preeclampsia based on gene expression profiles

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…These arguments, together with the recognition that late‐onset preeclampsia is predominantly related to a volume overloaded state, has initiated research into the value of diuretics in the management of late‐onset preeclampsia, with preliminary promising effects (Tamás et al . ). Magnesium sulphate is widely used for the prevention and treatment of maternal eclamptic seizures and for neonatal neuroprotection during preterm birth (Pryde & Mittendorf, ).…”

Section: Common Clinical Characteristics Of Cardiorenal Syndromes Andmentioning

confidence: 97%

“…The lack of terotogenic or clinical neonatal side effects in pregnancies with maintenance of chronic diuretic treatment or with acute cardiac or nephrological problems (von Dadelszen et al 2007;Al-Balas et al 2009), has stimulated the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy to formulate the statement that the concern for the use of diuretics in pregnancy should be considered primarily theoretical (NHBPEPWGHBPP, 2000;Brown & Garovic, 2014). These arguments, together with the recognition that late-onset preeclampsia is predominantly related to a volume overloaded state, has initiated research into the value of diuretics in the management of late-onset preeclampsia, with preliminary promising effects (Tamás et al 2017). Magnesium sulphate is widely used for the prevention and treatment of maternal eclamptic seizures and for neonatal neuroprotection during preterm birth (Pryde & Mittendorf, 2009).…”

Section: Pharmacotherapeutic Targetsmentioning

confidence: 99%

Preeclampsia: a gestational cardiorenal syndrome

Gyselaers

Thilaganathan

2019

The Journal of Physiology

View full text Add to dashboard Cite

It is generally accepted today that there are two different types of preeclampsia: an early‐onset or placental type and a late‐onset or maternal type. In the latent phase, the first one presents with a low output/high resistance circulation eventually leading in the late second or early third trimester to an intense and acutely aggravating systemic disorder with an important impact on maternal and neonatal mortality and morbidity; the other type presents initially as a high volume/low resistance circulation, gradually evolving to a state of circulatory decompensation usually in the later stages of pregnancy, with a less severe impact on maternal and neonatal outcome. For both processes, numerous dysfunctions of the heart, kidneys, arteries, veins and interconnecting systems are reported, most of them presenting earlier and more severely in early‐ than in late‐onset preeclampsia; however, some very specific dysfunctions exist for either type. Experimental, clinical and epidemiological observations before, during and after pregnancy are consistent with gestation‐induced worsening of subclinical pre‐existing chronic cardiovascular dysfunction in early‐onset preeclampsia, and thus sharing the pathophysiology of cardiorenal syndrome type II, and with acute volume overload decompensation of the maternal circulation in late‐onset preeclampsia, thus sharing the pathophysiology of cardiorenal syndrome type 1. Cardiorenal syndrome type V is consistent with the process of preeclampsia superimposed upon clinical cardiovascular and/or renal disease, alone or as part of a systemic disorder. This review focuses on the specific differences in haemodynamic dysfunctions between the two types of preeclampsia, with special emphasis on the interorgan interactions between heart and kidneys, introducing the theoretical concept that the pathophysiological processes of preeclampsia can be regarded as the gestational manifestations of cardiorenal syndromes.

show abstract

“…The lack of terotogenic or clinical neonatal side effects in pregnancies with maintenance of chronic diuretic treatment or with acute cardiac or nephrologic problems [159,160], has stimulated the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy to formulate the statement that the concern for the use of diuretics in pregnancy should be considered primarily theoretical [161,162]. These arguments, together with the recognition of two types of preeclampsia, has initiated research into the value of diuretics in the management of late onset preeclampsia, with preliminary promising effects [163].…”

Section: Implications For Clinical Practicementioning

confidence: 99%

Maternal Venous Hemodynamic Dysfunction in Proteinuric Gestational Hypertension: Evidence and Implications

Gyselaers

2019

JCM

View full text Add to dashboard Cite

This review summarizes current knowledge from experimental and clinical studies on renal function and venous hemodynamics in normal pregnancy, in gestational hypertension (GH) and in two types of preeclampsia: placental or early-onset preeclampsia (EPE) and maternal or late-onset (LPE) preeclampsia, presenting at <34 weeks and ≥34 weeks respectively. In addition, data from maternal venous Doppler studies are summarized, showing evidence for (1) the maternal circulation functioning closer to the upper limits of capacitance than in non-pregnant conditions, with intrinsic risks for volume overload, (2) abnormal venous Doppler measurements obtainable in preeclampsia, more pronounced in EPE than LPE, however not observed in GH, and (3) abnormal venous hemodynamic function installing gradually from first to third trimester within unique pathways of general circulatory deterioration in GH, EPE and LPE. These associations have important clinical implications in terms of screening, diagnosis, prevention and management of gestational hypertensive diseases. They invite for further hypothesis-driven research on the role of retrograde venous congestion in the etiology of preeclampsia-related organ dysfunctions and their absence in GH, and also challenge the generally accepted view of abnormal placentation as the primary cause of preeclampsia. The striking similarity between abnormal maternal venous Doppler flow patterns and those observed at the ductus venosus and other abdominal veins of the intra-uterine growth restricted fetus, also invites to explore the role of venous congestion in the intra-uterine programming of some adult diseases.

show abstract

Preliminary study of the effects of furosemide on blood pressure during late‐onset pre‐eclampsia in patients with high cardiac output

Cited by 19 publications

References 24 publications

Identifying key genes and drug screening for preeclampsia based on gene expression profiles

Identifying key genes and drug screening for preeclampsia based on gene expression profiles

Preeclampsia: a gestational cardiorenal syndrome

Maternal Venous Hemodynamic Dysfunction in Proteinuric Gestational Hypertension: Evidence and Implications

Contact Info

Product

Resources

About